Tags

Type your tag names separated by a space and hit enter

Glycaemic target attainment in people with Type 2 diabetes treated with insulin glargine/lixisenatide fixed-ratio combination: a post hoc analysis of the LixiLan-O and LixiLan-L trials.
Diabet Med. 2020 02; 37(2):256-266.DM

Abstract

AIMS

Both fasting (FPG) and postprandial plasma glucose (PPG) contribute to HbA1c levels. We investigated the relationship between achievement of American Diabetes Association (ADA) and American Association of Clinical Endocrinologists (AACE) recommended FPG and/or PPG targets and glycaemic efficacy outcomes in two trials.

METHODS

In this post hoc analysis, data from participants with Type 2 diabetes in the phase 3 LixiLan-O (NCT02058147) and LixiLan-L (NCT02058160) trials were evaluated to compare the relationship between achievement of society-recommended FPG and/or PPG targets and efficacy (HbA1c change, HbA1c goal attainment, weight change) and safety outcomes in the treatment groups.

RESULTS

Across treatment arms, iGlarLixi achieved the highest proportion of participants meeting both ADA- and AACE-recommended FPG and PPG targets at study end in both trials. A higher proportion of participants in the iGlarLixi (fixed-ratio combination of insulin glargine and lixisenatide) vs. insulin glargine alone or lixisenatide alone treatment arms achieved HbA1c goals (P < 0.001 for overall comparisons), irrespective of ADA- or AACE-defined targets. Hypoglycaemia rates [any, documented symptomatic (plasma glucose ≤ 3.9 mmol/l), and clinically important (plasma glucose < 3.0 mmol/l)] were low across all groups. Participants treated with iGlarLixi tended to show weight loss or less weight gain compared with participants receiving insulin glargine alone. No differences were observed in average daily basal insulin dose at week 30 between the two treatment arms or across the different FPG and PPG target groups.

CONCLUSION

Insulin glargine and lixisenatide as a fixed-ratio combination resulted in more participants reaching both FPG and PPG targets, leading to better HbA1c target attainment.

Authors+Show Affiliations

Touchstone Diabetes Center, Department of Internal Medicine, The University of Texas Southwestern Medical Center, Dallas, TX, USA.University of Nebraska Medical Center, Omaha, NE, USA.Tulane University Health Sciences Center, New Orleans, LA, USA.National Research Institute, Los Angeles, CA, USA.Antwerp University Hospital, Edegem-Antwerp, Belgium.University of Bari Aldo Moro, Bari, Italy.Xinyi, Inc., Bridgewater, NJ, USA.Sanofi US, Inc., Bridgewater, NJ, USA.Sanofi US, Inc., Bridgewater, NJ, USA.Sanofi US, Inc., Bridgewater, NJ, USA.Li Ka Shing Knowledge Institute, St. Michael's Hospital, University of Toronto, Toronto, ON, Canada.

Pub Type(s)

Journal Article
Research Support, Non-U.S. Gov't

Language

eng

PubMed ID

31365765

Citation

Davidson, J A., et al. "Glycaemic Target Attainment in People With Type 2 Diabetes Treated With Insulin Glargine/lixisenatide Fixed-ratio Combination: a Post Hoc Analysis of the LixiLan-O and LixiLan-L Trials." Diabetic Medicine : a Journal of the British Diabetic Association, vol. 37, no. 2, 2020, pp. 256-266.
Davidson JA, Desouza C, Fonseca V, et al. Glycaemic target attainment in people with Type 2 diabetes treated with insulin glargine/lixisenatide fixed-ratio combination: a post hoc analysis of the LixiLan-O and LixiLan-L trials. Diabet Med. 2020;37(2):256-266.
Davidson, J. A., Desouza, C., Fonseca, V., Frias, J. P., Van Gaal, L., Giorgino, F., Chao, J., Dex, T. A., Roberts, M., Saremi, A., & Leiter, L. A. (2020). Glycaemic target attainment in people with Type 2 diabetes treated with insulin glargine/lixisenatide fixed-ratio combination: a post hoc analysis of the LixiLan-O and LixiLan-L trials. Diabetic Medicine : a Journal of the British Diabetic Association, 37(2), 256-266. https://doi.org/10.1111/dme.14094
Davidson JA, et al. Glycaemic Target Attainment in People With Type 2 Diabetes Treated With Insulin Glargine/lixisenatide Fixed-ratio Combination: a Post Hoc Analysis of the LixiLan-O and LixiLan-L Trials. Diabet Med. 2020;37(2):256-266. PubMed PMID: 31365765.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Glycaemic target attainment in people with Type 2 diabetes treated with insulin glargine/lixisenatide fixed-ratio combination: a post hoc analysis of the LixiLan-O and LixiLan-L trials. AU - Davidson,J A, AU - Desouza,C, AU - Fonseca,V, AU - Frias,J P, AU - Van Gaal,L, AU - Giorgino,F, AU - Chao,J, AU - Dex,T A, AU - Roberts,M, AU - Saremi,A, AU - Leiter,L A, Y1 - 2019/11/26/ PY - 2019/07/29/accepted PY - 2019/8/1/pubmed PY - 2019/8/1/medline PY - 2019/8/1/entrez SP - 256 EP - 266 JF - Diabetic medicine : a journal of the British Diabetic Association JO - Diabet. Med. VL - 37 IS - 2 N2 - AIMS: Both fasting (FPG) and postprandial plasma glucose (PPG) contribute to HbA1c levels. We investigated the relationship between achievement of American Diabetes Association (ADA) and American Association of Clinical Endocrinologists (AACE) recommended FPG and/or PPG targets and glycaemic efficacy outcomes in two trials. METHODS: In this post hoc analysis, data from participants with Type 2 diabetes in the phase 3 LixiLan-O (NCT02058147) and LixiLan-L (NCT02058160) trials were evaluated to compare the relationship between achievement of society-recommended FPG and/or PPG targets and efficacy (HbA1c change, HbA1c goal attainment, weight change) and safety outcomes in the treatment groups. RESULTS: Across treatment arms, iGlarLixi achieved the highest proportion of participants meeting both ADA- and AACE-recommended FPG and PPG targets at study end in both trials. A higher proportion of participants in the iGlarLixi (fixed-ratio combination of insulin glargine and lixisenatide) vs. insulin glargine alone or lixisenatide alone treatment arms achieved HbA1c goals (P < 0.001 for overall comparisons), irrespective of ADA- or AACE-defined targets. Hypoglycaemia rates [any, documented symptomatic (plasma glucose ≤ 3.9 mmol/l), and clinically important (plasma glucose < 3.0 mmol/l)] were low across all groups. Participants treated with iGlarLixi tended to show weight loss or less weight gain compared with participants receiving insulin glargine alone. No differences were observed in average daily basal insulin dose at week 30 between the two treatment arms or across the different FPG and PPG target groups. CONCLUSION: Insulin glargine and lixisenatide as a fixed-ratio combination resulted in more participants reaching both FPG and PPG targets, leading to better HbA1c target attainment. SN - 1464-5491 UR - https://www.unboundmedicine.com/medline/citation/31365765/Glycaemic_target_attainment_in_people_with_Type_2_diabetes_treated_with_insulin_glargine/lixisenatide_fixed_ratio_combination:_a_post_hoc_analysis_of_the_LixiLan_O_and_LixiLan_L_trials_ L2 - https://doi.org/10.1111/dme.14094 DB - PRIME DP - Unbound Medicine ER -
Try the Free App:
Prime PubMed app for iOS iPhone iPad
Prime PubMed app for Android
Prime PubMed is provided
free to individuals by:
Unbound Medicine.